FDA advisory committee briefing documents range from damaging to devastating.
In this video, health-care analyst David Williamson discusses the briefing documents recently released by the FDA in advance of Delcath Systems and Aveo Pharmaceuticals advisory committee meetings. They range from damaging to devastating.
Watch and find out what sent shares of the two companies plummeting down 40% and 30% respectively and whether the sell-offs were deserved.
David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
